Sovaldi

Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Gilead’s Big Decade One strong...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) appear to be unaffected by reports that call into question the safety of hepatitis C drugs. The stock was trading higher by 0.47 percent at $72.25 ahead of Thursday's stock market open. According to Stat News, reports were filed with the U.S. Food and...

The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...

Barclays remains Overweight on Gilead Sciences, Inc. (NASDAQ: GILD) on valuation and franchise stability, despite reporting disappointing second-quarter results on the heels of hepatitis C drug Harvoni's continued sales declines. Harvoni, Sovaldi Sales for Harvoni plunged about 29 percent to $2.56...

Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (NYSE: MRK) on Monday stepped into court again, trying to settle a dispute regarding the validity of the latter's '499 and '712 patents, which Gilead’s Hepatitis C treatments Sovaldi/Harvoni were found to infringe...

Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily. Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89...

The Wall Street Journal highlighted a U.S. Senate report on Gilead Sciences, Inc. (NASDAQ: GILD) saying that the pharmaceutical giant knew high prices for its Hepatitis C drug would put the medicine out of reach for many patients that needed the treatment. The company priced its Solvaldi...

China’s State Intellectual Property Office (SIPO) has decided to reject a Gilead Sciences, Inc. (NASDAQ: GILD)’s patent application relating to its hepatitis C (HCV) drug sofosbuvir, marketed as Sovaldi. The rejection could have important implications for Gilead, its generic drug...

Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 3 percent early in Friday's session on earnings and news that first quarter revenue from its hepatitis C treatments rose sequentially by 19 percent to well ahead of Wall Street's estimates. Shares traded recently at $105.48, up 5...

Gilead Sciences, Inc. (NASDAQ: GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work. In its Q4 earnings report, Gilead announced that its cash position had increased from...